pharmaphorum

DECEMBER 4, 2020

Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. VLA15 has demonstrated a promising immune response and safety data in pre-clinical and clinical studies so far.

Vaccine 119

Vaccine Vaccination Bacterium Protein 119

Pharmaceutical Technology

OCTOBER 28, 2022

What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20. According to the UK’s National Health Service (NHS), there are over 90 strains of this bacterium. VAX-24 has forecasted sales of $21 million in the same year. billion and $812 million in 2028.

Vaccine 162

Vaccine Vaccination Marketing Bacteria 162

XTalks

JULY 28, 2021

Compared to Vaxneuvance’s targeting of 15 different strains of the bacterium, Pfizer’s shot protects against 20. billion in sales in 2020 and has been outselling Merck’s previous shot, Pneumovax 23, by almost five to one. This is seven more strains than its current winning vaccine Prevnar 13, which registered $5.95

FDA Approval 89

FDA Approval Vaccine Vaccination Immune Response 89

pharmaphorum

MAY 31, 2022

billion in sales last year. The pandemic and the timing of US government purchases for immunisation campaigns trimmed back sales from almost $5.9 The biotech says this can stimulate both B cell (antibody) and T cell immune responses with a single shot.

Vaccine 52

Vaccine Vaccination Bacterium Sales 52

pharmaphorum

JULY 14, 2021

The bulk of Prevnar 13 sales come from use in adults, and with Merck & Co in the final stages of regulatory review of its rival vaccine V114 – covering 15 serotypes and filed for adult use – the franchise is facing some serious competition for the first time. That is equivalent to 14% of Pfizer’s total revenues.

Immune Response 52

Immune Response Vaccine Vaccination Protein 52

The Pharma Data

JUNE 2, 2022

” In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. New GSK reaffirms its full-year 2022 guidance and the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**.

Vaccine 52

Vaccine Vaccination Immune Response Protein 52

The Pharma Data

MAY 31, 2022

In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. New GSK reaffirms its full-year 2022 guidance and the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**.

Vaccine 52

Vaccine Vaccination Immune Response Protein 52